Guardant Health (GH) 4: Freeman Chris bought 24,406 shares of Common Stock at $32.8… (May 26, 2026)

=== SEC Form 4 — Statement of Changes in Beneficial Ownership === Document Type: 4 Period of Report: 2026-05-22 10b5-1 Pre-arranged Plan: No --- Issuer --- Name: Guardant Health, Inc. (GH) CIK: 0001576280 --- Reporting Owner --- Name: Freeman Chris CIK: 0001871615 Role: Officer (Chief Commercial Officer) --- Non-Derivative Transactions --- [Transaction #1] Security: Common Stock Date: 2026-05-22 | Code: M (Exercise of derivative) Shares: +24,406 | Price: $32.86 Total Value: $801,981.16 Shares Owned After: 84,440 | Ownership: D (Direct) [Transaction #2] Security: Common Stock Date: 2026-05-22 | Code: S (Open market sale) Shares: -24,406 | Price: $118.67 Total Value: $2,896,360.08 Shares Owned After: 60,034 | Ownership: D (Direct) Footnotes: [F1] Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $118.55 to $118.97. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. --- Derivative Transactions --- [Transaction #1] Security: Stock Option (Right to Buy) Date: 2026-05-22 | Code: M (Exercise of derivative) Shares: -24,406 | Price: $0.00 Exercisable: N/A | Expires: 2033-06-09 Shares Owned After: 701 | Ownership: D (Direct) Footnotes: [F2] This represents a stock option award granted on June 9, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on June 9, 2024 and the remaining 67% of the shares subject to award vests each month during the two-year period thereafter. --- Footnotes (Complete Index) --- F1: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $118.55 to $118.97. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. F2: This represents a stock option award granted on June 9, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on June 9, 2024 and the remaining 67% of the shares subject to award vests each month during the two-year period thereafter. --- Signature --- /s/ /s/ John G. Saia, as attorney-in-fact for Chris Freeman (2026-05-26)